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Abstract
Background: Heat shock protein 70 (HSP70) has gained major attention as an adjuvant capable of inducing
antigen-specific CD8+ and CD4+ T-cell responses. The ability of HSP70/peptide complexes to elicit cytotoxic T-cell
(CTL) responses by cross-presentation of exogenous antigens via HLA class I molecules is of central interest in
immunotherapy. We examined the role of HSP70/CMVpp65495-503-peptide complex (HSP70/CMV-PC) in HLA class I-
restricted cross-presentation for ex vivo expansion of CMV-specific CTLs.
Methods: CMV-specific T cells generated from PBMCs of HLA-A*02:01/CMV-seropositive donors were stimulated for
21 days with HSP70/CMV-PC and analyzed in functional assays. As a control PBMCs were cultured in the presence
of CMVpp65495-503 peptide or HSP70. Increase of CMV-specific CTLs was visualized by pentameric HLA-A*02:01/
CMVpp65495-503 complex.
Results: About 90% of HSP70/CMV-PC generated T cells were CMV-specific and exhibited significantly higher IFN-g
secretion, cytotoxic activity, and an increased heme oxygenase 1 (HO-1) gene expression as compared to about
69% of those stimulated with CMVpp65495-503 peptide. We decided to classify the HLA-A*02:01/CMV-seropositive
donors as weak, medium, and strong responder according to the frequency of generated A2/CMV-pentamer-
positive CD8+ T cells. HSP70/CMV-PC significantly induces strong antiviral T-cell responses especially in those
donors with low memory precursor frequencies. Blockage of CD91 with a2-macroglobulin markedly reduced
proliferation of antiviral T cells suggesting a major role of this receptor in the uptake of HSP70/CMV-PC.
Conclusion: This study clearly demonstrates that HSP70/CMV-PC is a potent mediator to induce stronger T-cell
responses compared to antiviral peptides. This simple and efficient technique may help to generate significant
quantities of antiviral CTLs by cross-presentation. Thus, we propose HSP70 for chaperoning peptides to reach an
efficient level of cross-presentation. HSP70/peptide complexes may be particularly useful to generate stronger T-cell
responses in cases of low precursor frequencies and may help to improve the efficiency of antigen-specific T-cell
therapy for minor antigens.
Background
Heat shock proteins (HSPs) are highly conserved proteins
that function primarily as intracellular molecular chaper-
ones. Because of their ability to interact with proteins
and peptides, they play an important role in cell and
organ survival [1]. HSPs play a key role in protein
degradation, intracellular transport processes, protein
folding, and antigen processing. In apoptotic pathways,
they act at multiple points to prevent cells from inap-
propriate cell death triggered by stress-induced damage
[2]. The observation that tumor-derived preparations of
HSPs, such as glucose-regulated protein 96 (gp96),
HSP70, and HSP90 can elicit specific anti-tumor T-cell
immune responses, suggests that heat shock proteins
might have immunotherapeutic potential [3,4]. This* Correspondence: eiz-vesper.britta@mh-hannover.de1Institute for Transfusion Medicine, Hannover Medical School, Hannover,
Germany
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possibility is currently under investigation in clinical
trials [5-7].
The immunogenicity of HSP preparations is caused by
the binding of antigenic peptides to HSPs and from the
transfer of these peptides to professional antigen-present-
ing cells (APCs), such as dendritic cells (DCs). Peptides
chaperoned by HSPs are taken up in a receptor-dependent
manner and channeled into the major histocompatibility
complex (MHC) class I processing pathway for loading
onto MHC class I molecules and subsequent presentation
to CD8+ cytotoxic T lymphocytes (CTLs) [8,9]. Addition-
ally, heat shock proteins and HSP/peptide complexes
(HSP/PCs) can stimulate the maturation of APCs [10-12]
by efficiently interacting with receptors [13] such as CD91
[14,15], toll-like receptor (TLR) 2, TLR4 [16,17], Lox-1
[18], or CD40 [19].
Various groups have reported that in vitro generated
tumor-derived HSP/PCs are potent adjuvants to facilitate
the presentation of tumor antigens and the induction of
anti-tumor immunity [3,4]. However, it is widely unknown
whether viral peptides chaperoned by human HSPs are
sufficiently capable of cross-priming CD8+ antiviral T cells
[20]. Viral infections resulting from reactivation of latent
viruses such as cytomegalovirus (CMV), human adeno-
virus (ADV), and Epstein-Barr virus (EBV) are associated
with high morbidity and mortality after hematopoietic
stem cell transplantation (HSCT) [21-24] and solid organ
transplantation [25-27]. Antiviral agents such as ganciclo-
vir can reduce the incidence of early viral diseases, but are
associated with substantial toxicity and may result in
delayed immune reconstitution [28]. Previous studies have
shown that adoptive immunotherapy with donor-derived
virus-specific CTLs generated in vitro can safely and effi-
ciently prevent the clinical manifestation of these viral dis-
eases in patients following transplantation with no acute
toxicities or increased risk of graft-versus-host disease
(GvHD) [21,23,24,28].
In this study, we investigated whether an HSP/PC con-
sisting of HSP70 plus the immunodominant HLA-
A*02:01-restricted CMV peptide (CMVpp65495-503) [29]
can enhance cross-presentation of MHC class I molecules
and may therefore result in a higher specific antiviral T-
cell response compared to the stimulation with the peptide
alone. Most protocols for ex vivo activation and expansion
of antiviral T cells for adoptive immunotherapy use either
peptide-loaded DCs, artificial APCs (aAPCs), or CMV-
infected immature DCs as stimulator cells [30-33]. Addi-
tionally, researchers have focused on the whole CMVpp65
protein, whole viral lysates, virally infected cells, and var-
ious HLA-restricted viral peptides as a source of immuno-
dominant antigens stimulating both CTLs and T helper
(Th) cells [21,29,30,34]. The present study demonstrates
that cross-presentation of viral antigens by lipopolysac-
charide-(LPS) free HSP70 [35] significantly increases the
efficiency of the antiviral T-cell response. Our findings
highlight the role of extracellular HSP70 in the activation
of the adaptive immune response. The described method
for in vitro preparation of the HSP70/CMVpp65495-503-
peptide complex (HSP70/CMV-PC) and the generation of
CMV-specific CTLs can be adapted to GMP conditions
and used for therapeutic applications.
Methods
Preparation of HSP70/CMVpp65495-503-peptide complex
(HSP70/CMV-PC)
To facilitate eukaryotic expression and isolation, we devel-
oped an expression strategy for soluble human HSP70
secreted into the cell culture supernatant of mammalian
cells [35]. Purified endotoxin-free HSP70 was used to pre-
pare HSP70/CMV-PC under conditions similar to those
described elsewhere [36,37]. Briefly, 10 μg of HSP70 was
incubated at 37°C for 2 h with and without a 150-fold
molar excess of CMVpp65495-503 peptide (NLVPMVATV,
purity > 95%, Eurogentec, Seraing, Belgium) plus HSP70-
peptide-binding buffer (PBS with 1 mM ADP, 1 mM
MgCl2, pH 7.4) to yield a total volume of 100 μl. After
adding 2 ml PBS to the complex solution non-conjugated
peptide was removed completely by filtration through a
30 kDa molecular weight cutoff filter unit (Millipore,
Schwalbach, Germany). The final concentration of HSP70/
CMV-PC was determined by Bradford protein analysis. To
verify the concentration of free, uncomplexed peptide
remained in the spin column flow, additional independent
experiments (n = 5) were performed using fluorescein iso-
thiocyanate (FITC)-labeled CMVpp65495-503 peptide
((NLVPMK[FITC]VATV; CMV[FITC], purity > 95%, GL
Biochem, Shanghai, China) for preparation. After washing
the recovery of HSP70/CMV[FITC]-PC was determined
on a Synergy 2 Microplate Reader (Bio Tek Instruments,
Winooski, USA). The effective concentration of peptide
bound to HSP70 was calculated as the starting amount
(20 μg) minus the amount in the flow through. This count
corresponds to a loading efficiency of ~48% for the
(FITC)-labeled peptide on HSP70, which correspond to
the generation of about 10 μg/ml HSP70/CMV-PC.
Stimulation of antiviral T cells with HSP70, CMVpp65495-
503 peptide, and HSP70/CMV-PC
Baseline frequencies of CMV-specific T cells were deter-
mined prior to stimulation. Briefly, blood from 50 healthy
HLA-A*02:01/CMV-seropositive platelet donors with no
prior history of blood transfusion was stained with the
R-phycoerythrin (R-PE)-conjugated Pro5 pentamer
HLA-A*02:01/CMVpp65495-503 (A2/CMV-pentamer,
Proimmune, Oxford, UK) and fluorescein isothiocyanate
(FITC)-conjugated anti-CD8 monoclonal antibody, allo-
phycocyanin (APC)-conjugated monoclonal antibody, and
peridinin chlorophyll protein (PerCP)-conjugated
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monoclonal antibody (mAB, BD Biosciences, Heidelberg,
Germany), respectively. 100 μl whole blood samples were
then washed with 2 ml PBS and stained with A2/CMV-
pentamer and anti-CD8 antibody. After adding 2 ml
ammonium chloride lysis solution, the cells were incu-
bated for 10 min, washed twice with PBS and analyzed on
a flow cytometer (FACSCanto, BD Biosciences, Heidel-
berg, Germany).
T-cell stimulation was performed using samples from 16
A2/CMV-pentamer-positive donors. Peripheral blood
mononuclear cells (PBMCs) were isolated by discontinu-
ous gradient centrifugation, washed twice in sterile PBS,
resuspended at a concentration of 1 × 107 cells/ml in
RPMI1640 culture medium (Lonza, Vervies, Belgium), and
then supplemented with 10% heat-inactivated human AB
serum (C.C.pro, Neustadt, Germany) and 100 U/ml IL-2
(PeproTech, Hamburg, Germany). Cells were stimulated
in a 24-well plate with either 10 μg/ml HSP70, 10 μg/ml
CMVpp65495-503 peptide, or 10 μg/ml HSP70/CMV-PC.
HSP70-peptide-binding buffer was used as negative
control.
On days 7, 14, and 21, supernatants were harvested for
granzyme B and IFN-g secretion analyses by ELISA, and
the T cells were restimulated with autologous PBMCs
pulsed with the peptide or the complex. Briefly, 1 × 107
autologous PBMCs/ml were pulsed with HSP70,
CMVpp65495-503 peptide, or HSP70/CMV-PC overnight in
serum-free RPMI1640 medium. 2.5 × 105 T cells were res-
timulated with irradiated (30 Gy) PBMCs pulsed with the
peptide or the complex at a responder-to-stimulator ratio
of 10:1 in culture media containing 10% AB serum and
100 U/ml IL-2 (96-well round-bottom plate, 200 μl) for a
total of two restimulation cycles.
In order to determine the frequency of induced antiviral
T cells, the cells were stained weekly with the A2/CMV-
pentamer and the following mAbs: PerCP-conjugated
anti-CD8, FITC-conjugated anti-CD25, FITC-conjugated
anti-CD69, and APC-conjugated anti-CD137 (all from BD
Biosciences). All samples were analyzed on a flow cyt-
ometer with live gating on lymphocytes during acquisition.
For analysis, cells were gated on either CD8+ T cells or
A2/CMV-pentamer-positive CD8+ T cells. mRNA levels
of heme oxygenase 1 (HO-1, also referred to as HSP32)
and HSP70 were assessed every second day after stimula-
tion/restimulation and, finally, on day 21.
Determination of cytolytic activity
Cytolytic activity of induced antiviral T cells was deter-
mined once weekly after the first (day 14) and second
restimulation cycle (day 21) in a non-radioactive flow
cytometric assay using autologous CFSE [5- or 6-(N-
succinimidyloxicarbonyl)-3’,6’-O,O’-diacetylfluorescein)]-
labeled CMVpp65495-503 peptide-loaded autologous
PBMCs [38] as target cells. In order to exclude
alloreactivity the generated T cells were also tested
against unloaded CFSE-labeled PBMCs. Briefly, T cells
were incubated with target cells in 96-well round-bot-
tom plates at an effector to target cell ratio (E:T) of 10:1
and 1:1 in the presence of 20 U/ml IL-2 (PeproTech).
Target cell lysis was assessed by 7-aminoactinomycin D
(7-AAD, BD Biosciences) staining after 5 h.
T-cell proliferation assay and blocking of HSP70/CMV-PC
uptake by addition of a2-macroglobulin
To observe the expression levels of CD91 and CD40 we
stained freshly isolated PBMCs with PE-conjugated anti-
CD91 and PE-conjugated anti-CD40 (AbD Serotec, NC,
USA) and analyzed them by flow cytometry.
PBMCs from 5 A2/CMV-pentamer-positive donors
were labeled with CFSE (Invitrogen, Karlsruhe, Germany)
at a final concentration of 4 μM and plated at 5 × 105 cells
per well (96-well round-bottom plate) in 200 μl
RPMI1640/10% AB serum containing 100 U/ml IL-2.
Cells were stimulated for 4 days with either 10 μg/ml
HSP70, 10 μg/ml CMVpp65495-503 peptide, or 10 μg/ml
HSP70/CMV-PC. Unstimulated T cells were used as nega-
tive control.
To determine whether antiviral T-cell induction
occurred due to cross-presentation of peptides by HSP70,
the uptake of HSP70/CMV-PC was blocked by adding 500
μg/ml a2-macroglobulin (A2M, BioMac, Leipzig, Ger-
many), the natural ligand of CD91. Therefore, 5 × 105
CFSE-labeled PBMCs were pulsed prior to stimulation
with 500 μg/ml A2M for 1 hour and then stimulated for 4
days with 10 μg/ml HSP70, CMVpp65495-503 peptide, or
HSP70/CMV-PC. As negative control unstimulated A2M-
pulsed unstimulated T cells were used. T cells were
stained with APC-conjugated anti-CD8 mAb and R-PE-
conjugated A2/CMV-pentamer and the effect of stimula-
tion with HSP70, CMVpp65495-503 peptide, and HSP70/
CMV-PC with or without A2M on CD8+ and A2/CMV-
pentamer-positive CD8+ T-cell proliferation was analyzed
by flow cytometry.
Determination of HSP70 and HO-1 mRNA levels by
quantitative RT-PCR
HSP70 and HO-1 mRNA levels were determined every
second day after stimulation/restimulation and, finally, on
day 21. Total cellular RNA was isolated (RNeasy Mini Kit,
Qiagen) and cDNA amplified using the High Capacity
cDNA Reverse Transcription Kit (Applied Biosystems,
Darmstadt, Germany) for this purpose. Inventoried mixes
(Applied Biosystems) were used for quantification of
HSP70 and HO-1 mRNA levels. Amplification was per-
formed using TaqMan Gene Expression Master Mix
(Applied Biosystems). Thermal cycling was performed on
a StepOnePlus real-time PCR system (Applied Biosystems)
at 50°C for 15 min and 95°C for 10 min followed by
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40 cycles at 95°C for 15 sec and 60°C for 1 min. The con-
stitutively expressed GAPDH gene was used as the refer-
ence standard for normalization of mRNA levels.
Determination of granzyme B and IFN-g secretion by
ELISA
Granzyme B and IFN-g secretion in the supernatant of
cells cultured in the presence of HSP70-peptide-binding
buffer (negative control), HSP70, CMVpp65495-503 peptide,
or HSP70/CMV-PC was measured on days 7, 14, and 21.
Granzyme B (Bender MedSystems, Vienna, Austria) and
IFN-g (eBioscience, San Diego, USA) ELISAs were per-
formed according to the manufacturer’s instructions.
Statistics
Statistical analyses were performed using t-test run on
GRAPHPAD PRISM V5.02 software (GraphPad Software,
San Diego, California, USA). Levels of significance are
expressed as p-values (*p < 0.05, **p < 0.01, ***p < 0.001).
Results
Induction and expansion of antiviral T-cell populations
in response to HSP70, CMVpp65495-503 peptide, and
HSP70/CMV-PC
We have previously developed a method for the expres-
sion of endotoxin-free recombinant human HSP70 [35],
which was used in this study to chaperone viral peptides
into the MHC class I cross-presentation pathway to
increase the efficiency of the antiviral T-cell response.
Human HSP70 preparations containing less than 1 EU/ml
endotoxin were defined as endotoxin-free.
To directly visualize CMV-specific T cells in the blood
of healthy donors before stimulation, we stained whole
blood from 50 HLA-A*02:01/CMV-seropositive donors
with the A2/CMV-pentamer and anti-CD8 antibody. The
pentamer bound 0.30% to 6.70% (mean 1.91%) of CD8+ T
cells in 26/50 (52.00%) HLA-A*02:01-positive donors. No
A2/CMV-pentamer-positive T cells (< 0.30% A2/CMV-
pentamer+CD8+ T cells) were detected in 24 donors
(48.00%). PBMCs from sixteen A2/CMV-pentamer-posi-
tive donors (mean 1.62%, range 0.30%-5.64%) were
selected for further analysis (Table 1). The frequency and
activation status of antiviral T cells stimulated with human
HSP70, CMVpp65495-503 peptide, or HSP70/CMV-PC,
respectively, were assayed weekly by determining the per-
centage of T cells stained positive for A2/CMV-pentamer,
CD8, CD4, CD25, CD69, and CD137, respectively. Table 2
shows the frequencies of CD8+ T cells on day 0 and after
7, 14, and 21 days of stimulation under the described
conditions.
The highest frequencies of CD8+ T cells were
observed on days 7 to 21 in cells stimulated with the
complex with means ranging from 27.27% ± 0.95 to
83.17% ± 5.30 (Table 2). Data sets from 16 healthy
HLA-A*02:01/CMV-seropositive donors were divided
into 3 responder groups: weak, medium, and strong,
respectively (Figure 1A and 1B, Table 1), according to
the obtained frequency of generated A2/CMV-penta-
mer-positive CD8+ T cells after 7 days of stimulation
with the CMVpp65495-503 peptide. Classification of
groups was performed as followed: the group of weak
responders included 5 donors with < 1% A2/CMV-pen-
tamer-positive CD8+ T cells (mean 0.29%, range 0.14%-
0.50%) and the group of medium responders contained
5 donors with 1-10% A2/CMV-pentamer-positive CD8+
T cells (mean 3.29%, range 1.11%-5.19%). The group of
strong responders consisted of 6 donors with > 10% A2/
CMV-pentamer-positive CD8+ T cells (mean 20.88%,
range 13.54%-37.76%) after one week of stimulation.
Flow cytometric results of the stimulation experiments
for one representative donor from each group are shown
(Additional file 1). Both the peptide and the complex sig-
nificantly increased populations of A2/CMV-pentamer-
positive CD8+ T cells in all donors tested (Figure 1A and
1B), whereas HSP70 or HSP70-peptide-binding buffer
alone (negative controls) have no effect on T-cell induc-
tion. As shown in Figure 1A, on day 7 the number of A2/
CMV-pentamer-positive CD8+ T cells induced by the
complex (weak: mean 0.56%, medium: mean 9.22%, strong:
mean 43.78%) was higher than those induced by the pep-
tide alone (weak: mean 0.29%, medium: mean 3.29%,
strong: mean 20.88%). On day 14 the A2/CMV-pentamer-
positive CD8+ T-cell frequencies induced by the complex
(weak: mean 4.09%, medium: mean 46.68%, strong: mean
82.35%) were significantly higher than those achieved by
the peptide alone (weak: mean 0.69%, medium: mean
29.20%, strong: mean 50.80%). The highest frequencies of
A2/CMV-pentamer-positive CD8+ T cells (weak: mean
11.03%, medium: mean 63.57%, strong: mean 90.08%)
were observed on day 21 in cells treated with HSP70/
CMV-PC, which were significantly higher than those
induced by the peptide alone (weak: mean 2.32%, medium:
mean 44.02%, strong: mean 69.12%).
The frequencies of A2/CMV-pentamer-positive CD8+ T
cells correlate with the obtained cell numbers of A2/
CMV-pentamer-positive CD8+ T cells (Figure 1B). From
day 0 to day 21 the increase in A2/CMV-pentamer-posi-
tive CD8+ T cells induced by the complex (weak: mean
3.90 × 104 to 3.82 × 106 /97.95-fold, medium: mean 8.12 ×
104 to 8.12 × 107 /1000-fold, strong: mean 1.78 × 105 to
2.78 × 108 /1564.3-fold) was significantly higher than
those achieved by the peptide alone (weak: mean 3.90 ×
104 to 7.60 × 105 /19.5-fold, medium: mean 8.12 × 104 to
1.10 × 107 /135.4-fold, strong: mean 1.78 × 105 to 6.81 ×
107 /383.5-fold).
To sum up, from day 7 forth the highest frequencies
and cell numbers of A2/CMV-pentamer-positive CD8+ T
cells were induced by HSP70/CMV-PC. Especially in
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donors with low memory precursor frequencies, the sti-
mulation with the complex resulted in a significantly
higher level of antigen-specific CD8+ T cells compared to
the stimulation with the viral peptide alone.
Because CD25, CD69, and CD137 are suitable surface
markers to differentiate antigen-specific T cells [39], they
were used to further characterize CD8+ (Table 2) and
A2/CMV-pentamer-positive CD8+ T cells (Table 2).
Expression of all three markers increased after 14 days in
CD8+ T cells. As expected, expression levels of all mar-
kers in A2/CMV-pentamer-positive CD8+ T cells were
higher than those in CD8+ T cells. Furthermore, the
highest expression levels were observed in all A2/CMV-
pentamer-positive CD8+ populations on day 7 which sig-
nificantly decreases up to day 21. Expression levels were
slightly higher in CD8+ T cells and A2/CMV-pentamer-
positive CD8+ T cells, respectively stimulated with
HSP70/CMV-PC as compared to those stimulated with
CMVpp65495-503 peptide alone.
Cytolytic activity of induced antiviral T cells
To examine whether induced antigen-specific T cells
were functional, a non-radioactive cytotoxicity assay was
performed. Cytolytic activity of CMVpp65495-503 peptide-
and HSP70/CMV-PC-induced CTLs from 16 healthy
HLA-A*02:01/CMV-seropositive donors were analyzed
after one and two restimulation cycles (Figure 1C). As a
control T cells were cultured in the presence of HSP70
or HSP70-peptide-binding buffer. The lytic function of
the CTLs was assayed by E:T cell ratios of 10:1 and 1:1.
CFSE-labeled PBMCs pulsed with CMVpp65495-503 pep-
tide were used as target cells. Additionally to exclude
unspecific cytolytic function of the effector cells, non-
pulsed PBMCs were used as target cells as well. The
basal cytolytic activity of effector T cells against the non-
pulsed target cells was subtracted from the specific cyto-
lytic values. The results are expressed as the mean per-
centage of target cell lysis ± standard deviation. In all
three responder groups, unstimulated T cells and
HSP70-induced T cells exhibited the lowest levels of
cytolytic activity (data not shown). The specific lysis of
CMVpp65495-503 peptide-pulsed target cells by induced
antiviral CTLs increased from the first to the second res-
timulation cycle at both E:T ratios.
The highest cytolytic activity was observed for HSP70/
CMV-PC-induced CTLs at an E:T ratio of 10:1 on day 14
(weak: 9.05%, medium: 21.71%, strong: 45.52%) and on
day 21 (weak: 20.62%, medium: 33.41%, strong: 60.12%).
The killing was significant higher compared CMVpp65495-
503 peptide-induced CTLs (weak: 3.25% and 7.55%,
medium: 14.65% and 21.64%, strong: 25.14 and 34.37%).
Co-culturing at an E:T ratio of 1:1 showed similar results.
In summary, in all three groups the cytolytic activity of
T cells stimulated with HSP70/CMV-PC was sig-
nificantly higher than that of CTLs stimulated with the
CMVpp65495-503 peptide alone. These findings indicate
Table 1 Classification of the three responder groups (weak, medium, and strong) after stimulation with CMVpp65495-
503 peptide
day 0 day 7
donor percentage of
pentamer+CD8+ T cells
absolute number of pentamer
+CD8+ T cells [x106]
percentage of
pentamer+CD8+ T cells
absolute number of pentamer
+CD8+ T cells [x106]
responder
classification
1 0.40 0.04 0.30 0.02 weak
2 0.39 0.04 0.19 0.02 weak
3 0.39 0.04 0.34 0.06 weak
4 0.37 0.04 0.50 0.07 weak
5 0.40 0.04 0.14 0.02 weak
6 0.30 0.03 4.50 0.56 medium
7 0.53 0.05 5.19 0.36 medium
8 2.17 0.22 2.75 0.17 medium
9 0.79 0.08 2.89 0.38 medium
10 0.30 0.03 1.11 0.19 medium
11 0.65 0.07 37.76 4.34 strong
12 5.64 0.56 13.54 1.15 strong
13 0.56 0.06 21.00 1.26 strong
14 1.40 0.14 16.67 2.17 strong
15 0.70 0.07 16.80 1.60 strong
16 1.70 0.17 19.50 1.37 strong
The data sets from 16 healthy HLA-A*02:01/CMV-seropositive donors were divided into 3 responder groups: weak (n = 5), medium (n = 5), and strong (n = 6),
respectively, according to the obtained frequency of generated A2/CMV-pentamer-positive CD8+ T cells after 7 days of stimulation with the CMVpp65495-503
peptide (weak responders < 1% A2/CMV-pentamer-positive CD8+ T cells, medium responders 1-10% A2/CMV-pentamer-positive CD8+ T cells, strong responders >
10% A2/CMV-pentamer-positive CD8+ T cells).
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Table 2 Antiviral T-cell frequencies generated by the different stimuli
A. Percentage of CD8+ T cells#
CD8+ T cells (day 0: 20.22 ± 1.89)
day 7 day 14 day 21
NC 25.48 ± 1.93 33.80 ± 20.15 41.92 ± 23.91
HSP70 25.20 ± 2.50 36.52 ± 12.65 47.70 ± 28.96
CMVpp65495-503 peptide 27.07 ± 1.22 61.43 ± 11.61 63.06 ± 25.79
HSP70/CMV-PC 27.27 ± 0.95 79.83 ± 11.36** 83.17 ± 5.30*
#cells were gated on viable lymphocytes
B. Percentage of CD25+, CD69+, and CD137+ T cells□
CD25+ T cells (day 0: 1.29 ± 0.21)
day 7 day 14 day 21
NC 0.17 ± 0.29 0.23 ± 0.10 0.08 ± 0.04
HSP70 0.13 ± 0.23 0.28 ± 0.15 0.18 ± 0.08
CMVpp65495-503 peptide 0.77 ± 0.29 36.18 ± 13.12 5.40 ± 5.29
HSP70/CMV-PC 1.74 ± 0.81 38.25 ± 8.16 18.10 ± 0.57*
CD69+ T cells (day 0: 13.62 ± 4.70)
NC 0.10 ± 0.10 0.23 ± 0.10 0.18 ± 0.18
HSP70 0.10 ± 0.10 0.30 ± 0.14 0.24 ± 0.27
CMVpp65495-503 peptide 0.73 ± 0.22 2.68 ± 1.18 3.68 ± 4.18
HSP70/CMV-PC 1.33 ± 0.59 2.18 ± 0.35 5.82 ± 7.71
CD137+ T cells (day 0: 2.39 ± 0.01)
NC 0.10 ± 0.10 0.10 ± 0.08 0.04 ± 0.05
HSP70 0.07 ± 0.06 0.15 ± 0.06 0.14 ± 0.09
CMVpp65495-503 peptide 0.70 ± 0.17 12.77 ± 4.24 6.60 ± 1.39
HSP70/CMV-PC 1.50 ± 0.52* 25.10 ± 4.67* 14.15 ± 5.87*
□cells were gated on CD8+ T cells
C. Percentage of CD25+, CD69+, and CD137+ T cells○
CD25+ T cells (day 0: 5.98 ± 0.33)
day 7 day 14 day 21
NC 51.03 ± 44.41 49.46 ± 43.74 51.03 ± 56.44
HSP70 49.57 ± 43.27 48.62 ± 45.50 50.50 ± 55.42
CMVpp65495-503 peptide 87.37 ± 2.90 72.90 ± 25.77 73.03 ± 45.76
HSP70/CMV-PC 89.50 ± 5.40 78.55 ± 24.43 72.40 ± 47.37
CD69+ T cells (day 0: 16.49 ± 10.89)
NC 5.45 ± 4.74 10.73 ± 4.10 2.63 ± 4.56
HSP70 5.85 ± 3.89 12.08 ± 6.67 6.17 ± 8.45
CMVpp65495-503 peptide 84.30 ± 0.52 2.93 ± 1.31 0.50 ± 0.44
HSP70/CMV-PC 84.93 ± 12.00 3.07 ± 1.24 0.63 ± 0.58
CD137+ T cells (day 0: 11.86 ± 1.01)
NC 2.60 ± 2.40 4.23 ± 3.10 3.30 ± 1.87
HSP70 4.00 ± 3.82 8.45 ± 4.63 4.83 ± 3.61
CMVpp65495-503 peptide 88.05 ± 3.04 15.45 ± 7.19 10.73 ± 8.39
HSP70/CMV-PC 92.45 ± 5.87 17.05 ± 14.79 11.45 ± 9.73
○cells were gated on A2/CMV-pentamer-positive CD8+ T cells
We assessed the capacity of T-cell subpopulations from five A2/CMV-pentamer-positive healthy donors to generate antiviral T cells in the presence of HSP70,
CMVpp65495-503 peptide, or HSP70/CMV-PC by enumerating the following specific T cells by flow cytometry. (A) CD8
+ T cells gated on viable lymphocytes, (B)
CD25+, CD69+, and CD137+ cells gated on CD8+ T cells and (C) CD25+, CD69+, and CD137+ cells gated on A2/CMV-pentamer-positive CD8+ T cells. PBMCs
cultured in the presence of HSP70-peptide-binding buffer were used as negative controls (NC). The results of 5 independent experiments using cells from
medium responder are expressed as mean ± SD. Asterisks shown indicate only statistically significant differences between levels in CMVpp65495-503 peptide- and
HSP70/CMV-PC-stimulated cells (* p < 0.05, ** p < 0.01 or *** p < 0.001).
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Figure 1 HLA-A*02:01/CMV-pentamer staining, number of A2/CMV-pentamer-positive CD8+ T cells, and cytolytic function of antigen-
specific CTLs stimulated with HSP70/CMV-PC and CMVpp65495-503 peptide. Frequency (A) and number (B) of HLA-A*02:01/CMV-pentamer-
positive CD8+ CTLs from 16 healthy HLA-A*02:01/CMV-seropositive platelet donors on day 0 and 7, 14, and 21 days after stimulation with
recombinant HSP70, CMVpp65495-503 peptide, or HSP70/CMV-PC. Cells cultured in the presence of the HSP70-peptide-binding buffer served as
negative controls (NC). The 16 donors were divided into three groups (weak: n = 5, medium: n = 5, strong: n = 6) according to the frequency of
generated A2/CMV-pentamer-positive CD8+ T cells on day 7. Cytolytic activity (C) of expanded T cells against antigen-loaded PBMCs after one
(day 14) and two (day 21) restimulation cycles in cells from 16 healthy HLA-A*02:01/CMV-seropositive donors. CFSE-labeled PBMCs unloaded or
loaded with CMVpp65495-503 peptide were used as target cells. T cells generated for 14 or 21 days in the presence of the CMVpp65495-503
peptide or HSP70/CMV-PC (effector cells) were co-cultured with target cells for 5 h at a cell ratio of 10:1 or 1:1, respectively. The basal cytotoxic
activity of effector T cells induced by CMVpp65495-503 peptide or HSP70/CMV-PC against the unloaded target cells was subtracted from the
cytotoxic values measured after incubation of effector T cells against CMVpp65495-503 peptide-loaded PBMCs. The results of independent
experiments are expressed as mean ± SD. Asterisks shown in the Figure indicate only statistically significant differences between levels in
CMVpp65495-503 peptide- and HSP70/CMV-PC-stimulated cells (* p < 0.05, ** p < 0.01, *** p < 0.001).
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that T cells stimulated with HSP70/CMV-PC are cytolyti-
cally active and recognize endogenously processed
CMVpp65 antigen-HLA complexes more effectively than
T cells stimulated with peptide alone.
Inhibition of T-cell proliferation and blockage of HSP70/
CMV-PC uptake by A2M
Figure 2 shows the flow cytometric results of 5 indepen-
dent experiments using cells from donors of group med-
ium responders for antigen-specific T-cell proliferation
in response to HSP70, CMVpp65495-503 peptide, and
HSP70/CMV-PC. In Figure 2A the results of proliferation
of CD8+ T cells are shown, whereas in Figure 2B the
results of proliferation of A2/CMV-pentamer-positive
CD8+ T cells are shown. PBMCs (19.46% ± 9.05 CD8+
T cells, 0.96% ± 0.56 A2/CMV-pentamer-positive CD8+
T cells) were labeled with CFSE and stimulated with
HSP70, CMVpp65495-503 peptide, and HSP70/CMV-PC,
respectively. The lowest proliferation of CD8+ T cells was
observed on day 4 for cells stimulated with HSP70 alone
(3.14% ± 0.89%, Figure 2A). Proliferation of CD8+ T cells
was significantly higher in cells cultured in the presence
of HSP70/CMV-PC (25.09% ± 8.37%) as compared to
CMVpp65495-503 peptide (6.11% ± 2.71%) alone. The
increase in proliferation was even more pronounced
when analyzing the proliferation of A2/CMV-pentamer-
positive CD8+ T cells (Figure 2B) in the different culture
conditions. Again stimulation of cells with HSP70/CMV-
PC (13.75% ± 3.67%) resulted in a significantly higher
increase of CMV-specific T cells as compared to stimula-
tion with CMVpp65495-503 peptide (2.92% ± 1.22%) or
HSP70 (0.71% ± 0.47%).
To determine whether the induction of antiviral T cells
after stimulation with HSP70/CMV-PC was the result of
cross-presentation of chaperoned peptides, the uptake of
the complex by the CD91 receptor was blocked with
A2M. On day 0, the frequency of CD91 expression on
PBMCs of the 5 donors was 26.10% ± 10.92% and of
CD40 expression 23.13% ± 16.87%. Addition of A2M to
isolated PBMCs significantly reduced the proliferation of
CD8+ T cells (Figure 2A) as well as A2/CMV-pentamer-
positive CD8+ T cells (Figure 2B) in response to HSP70
and HSP70/CMV-PC. Incubation with A2M prior to sti-
mulation with the complex resulted in a reduced prolifera-
tion of 86.86% (from 25.09% ± 8.37 to 3.30% ± 1.45) for
CD8+ T cells and of 87.28% (from 13.75% ± 3.67 to 1.75%
± 0.18) for A2/CMV-pentamer-positive CD8+ T cells. The
proliferation of T cells in unstimulated cultures as well as
CMVpp65495-503 peptide-induced T cells remains unaf-
fected. Proliferation of CMV-specific T cells is induced by
presentation of the viral peptide chaperoned by HSP70
and can be blocked by adding A2M, the natural ligand of
CD91.
Real-time RT-PCR assessment of target-dependent HSP70
and HO-1 mRNA levels
In order to determine whether the expression of HSP70
and HO-1 is affected by recombinant HSP70,
CMVpp65495-503 peptide, and HSP70/CMV-PC we mea-
sured levels of HSP70 and HO-1 mRNA by real-time PCR
at various time points (Figure 3). Unstimulated T cells
were used as negative control and the relative quantifica-
tion (RQ) values for these experiments were adjusted to
1.00. HSP70 (Figure 3A-C) and HO-1 (Figure 3D-F)
Figure 2 Effects of HSP70, CMVpp65495-503 peptide, and HSP70/CMV-PC in the presence/absence of a2-macroglobulin on T-cell
proliferation. PBMCs were labeled with CSFE and cultured with HSP70-peptide-binding buffer (NC), HSP70, CMVpp65495-503 peptide, or HSP70/
CMV-PC for 4 days. Cell proliferation within the CD8+ (A) and the A2/CMV-pentamer-positive CD8+ (B) T-cell populations was evaluated by CFSE
dilution. In order to determine whether antiviral T-cell induction occurred due to cross-presentation of peptides by HSP70, the uptake of HSP70/
CMV-PC was blocked by adding a2-macroglobulin (A2M). The results of 5 independent experiments using cells from medium responder are
expressed as mean ± SD. Asterisks shown in the Figure indicate only statistically significant differences between levels in CMVpp65495-503
peptide- and HSP70/CMV-PC-stimulated cells (* p < 0.05, ** p < 0.01, *** p < 0.001).
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mRNA levels were up-regulated in response to HSP70,
CMVpp65495-503 peptide, and HSP70/CMV-PC in all 3
groups of tested donors. Stimulation with HSP70 caused
an induction of the mRNA levels of HSP70 (Figure 3A-C)
from day 2 to day 21 (weak: 0.25 to 1.61, medium: 1.58 to
2.21, strong: 1.70 to 3.44). Stimulation with the HSP70/
CMV-PC lead to a significant induction of mRNA levels
(weak: 1.78 to 5.48, medium: 4.84 to 15.41, strong: 9.80 to
25.50) compared to stimulation with the CMVpp65495-503
peptide (weak: 0.99 to 3.12, medium: 1.91 to 7.70, strong:
4.77 to 13.97) alone. Likewise, HO-1 mRNA (Figure 3D-F)
levels in the groups of weak/medium/strong responders
were 1.02 to 4.65/1.34 to 8.25/2.29 to 9.67 in response to
HSP70 and increased significantly in response to
CMVpp65495-503 peptide (weak: 1.52 to 9.35, medium:
2.85 to 13.42, strong: 8.66 to 18.75) and HSP70/CMV-PC
(weak: 2.49 to 15.82, medium: 5.32 to 25.58, strong: 16.41
to 40.81). In general, in comparison to peptide stimulation
levels of HSP70 and HO-1 mRNA were significantly
higher in all experiments in the HSP70/CMV-PC-stimu-
lated T cells.
Stimulation with HSP70/CMV-PC up-regulates early IFN-g
and granzyme B secretion
Secretion levels of the Th1 cytokine IFN-g (Figure 4A) and
the effector molecule granzyme B (Figure 4B) were mea-
sured in the supernatant of cells stimulated with HSP70,
CMVpp65495-503 peptide, or HSP70/CMV-PC by ELISA
on days 7, 14, and 21. Unstimulated PBMCs did not
secrete high amounts of IFN-g or granzyme B. The highest
amounts of IFN-g and granzyme B were detected in super-
natants of cells stimulated with HSP70/CMV-PC. From
day 7 to day 21 the IFN-g levels of PBMCs stimulated with
HSP70 (weak: 35.0 to 91.5 pg/ml, medium: 413.9 to 505.1
pg/ml, strong: 752.3 to 1224.1 pg/ml), CMVpp65495-503
peptide (weak: 220.8 to 687.4 pg/ml, medium: 1168.2 to
1906.6 pg/ml, strong: 2206.3 to 5153.2 pg/ml), and
HSP70/CMV-PC (weak: 1372.0 to 1890.0 pg/ml, medium:
Figure 3 mRNA expression levels of HSP70 and HO-1 determined by quantitative real-time RT-PCR. mRNA expression levels of HSP70 (A-
C) and HO-1 (D-F) for antigen-specific T cells of donors divided in weak (A, D), medium (B, E), and strong (C, F) after stimulation with HSP70,
CMVpp65495-503 peptide, and HSP70/CMV-PC were determined by real-time RT-PCR. Constitutively expressed GAPDH gene was used as the
reference standard for normalization of mRNA levels. Expression levels of mRNA were measured every second day after stimulation/restimulation
and, finally, on day 21. The results of independent experiments are expressed as means (weak: n = 5, medium: n = 5, strong: n = 6). RQ values
were calculated by the delta-delta CT method.
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3985.8 to 4883.9 pg/ml, strong: 6768.7 to 10527.1 pg/ml)
were significantly higher than those in unstimulated
PBMCs. An increase in granzyme B secretion from day
7 to day 21 was observed in cells cultured in the presence
of HSP70 (weak: 169.0 to 506.0 pg/ml, medium: 336.8
to 732.7 pg/ml, strong: 1169.9 to 1572.7 pg/ml),
CMVpp65495-503 peptide (weak: 205.9 to 1341.1 pg/ml,
medium: 1276.3 to 2011.3 pg/ml, strong: 3715.5 to 7384.3
pg/ml), and HSP70/CMV-PC (weak: 503.6 to 2723.4 pg/
ml, medium: 3060.7 to 3881.9 pg/ml, strong: 7015.89 to
16288.8 pg/ml).
Interestingly, compared to peptide-stimulated cells in
HSP70/CMV-PC-induced T cells a significantly higher
secretion of IFN-g and granzyme B was determined.
Discussion
In this study, LPS-free recombinant human HSP70 was
used to increase the antiviral T-cell response to
CMVpp65495-503 peptide, the well-known HLA-A*02:01-
restricted peptide. For this purpose, HSP70/CMV-PC
generated in vitro was used to stimulate cytotoxic T cells
from unfractionated PBMCs of HLA-A*02:01/CMV-sero-
positive donors. Our data suggest that linking HSP70 to
the CMVpp65495-503 peptide can increase antiviral CD8
+
T-cell activation and induces a more active phenotype
compared to CMVpp65495-503 peptide alone. Previous
studies have described the adjuvant effects of HSPs fol-
lowing antigen association during the induction of anti-
tumor activity [36,37]. Our study is the first to demon-
strate that human HSP70 complexed with immunodomi-
nant HLA-A*02:01-restricted CMVpp65 peptide
(CMVpp65495-503) enhances specific antiviral CD8
+ CTL
responses, especially in donors with low memory CTL
precursor frequencies. This strategy opens the stage for
GMP-conform improvements of adoptive immunothera-
peutic protocols.
CMV infections are a major complication following
HSCT and associated with high morbidity and mortality.
Adoptive immunotherapy with antigen-specific T cells
appears to be a promising treatment for reconstitution of
anti-CMV immunity. Therefore, major efforts have been
made to identify essential immunogenic CMV-derived
epitopes to generate sufficient amounts of antiviral T
cells for adoptive transfer. In recent years, two CMV pro-
teins - phosphoprotein 65 (pp65) and immediate-early
protein-1 (IE-1) - were found to be major immunodomi-
nant targets for the induction of antiviral CD4+ and CD8
+ T-cell responses and are considered as candidates for
vaccine design [21,40]. About 70% of CMV-specific CTLs
recognize pp65-derived epitopes presented by HLA class
I molecules [41]. We utilized the immunogenic HLA-
A*02:01-restricted CMVpp65495-503 peptide [29,42] as a
viral target and observed that cross-presentation of this
peptide by recombinant HSP70 yielded in a significantly
higher number of antigen-specific T cells compared to
the use of the CMVpp65495-503 peptide alone. Expression
of soluble HSP70 in mammalian cells was recently estab-
lished to prevent pathogen-associated molecular pattern
(PAMP) contamination [35].
Several studies have shown that HSP/PCs can induce
efficient cell-mediated immunity to human tumor antigens
and improve the frequency of antigen-specific cytotoxic
CD8+ T cells [43-45]. It is known, that the adaptive
immune response is initiated by receptor-mediated endo-
cytosis of the HSP/PCs (Additional file 2), which deliver
the peptides via both cytosolic and endocytic routes of
antigen processing for cross-presentation in MHC class I
molecules on the surface of APCs [8,44,46,47]. So far, only
CD91 [14] has been shown to be a key receptor for the
uptake and cross-presentation of HSP70/PCs. We likewise
observed that A2M, which acts as a natural ligand for
CD91 [46,48], strongly inhibits the proliferation of antiviral














































Figure 4 Detection of IFN-g and granzyme B protein secretion by ELISA. The capacity of T cells to secrete cytokines and effector molecules
was assessed by determining the secretion levels of (A) the Th type 1 (Th1) cytokine IFN-g and (B) granzyme B by ELISA. After stimulation with
HSP70, CMVpp65495-503 peptide, and HSP70/CMV-PC the T-cell culture supernatants were harvested on days 7, 14, and 21 and used for analysis.
The results of independent experiments are expressed as means (weak: n = 5, medium: n = 5, strong: n = 6) are expressed as mean ± SD.
Asterisks shown in the Figure indicate only statistically significant differences between levels in CMVpp65495-503 peptide- and HSP70/CMV-PC-
stimulated cells (* p < 0.05, ** p < 0.01, *** p < 0.001).
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T cells stimulated with HSP70/CMV-PC. When inhibition
was ≤ 86.86% (CD8+ T cells) and ≤ 87.26% (A2/CMV-pen-
tamer-positive CD8+ T cells), the proliferation capacity of
antiviral T cells was not completely blocked. These find-
ings indicate that the uptake of HSP70/PCs is mainly
mediated by CD91, but other independent receptor sys-
tems of APCs could also be involved. Here CD40- [19]
and LOX-1-mediated uptake [18,49] might play a role.
The frequency of antiviral CD8+ T cells increased signif-
icantly in all stimulation groups, but varied depending on
the individual donor PBMCs. It is well known that the fre-
quencies of CMV-specific T cells can range from roughly
2 to 10 percent to more than 70 to 90 percent, even in
individuals who are clearly responders [31]. We demon-
strated that only 52.00% of 50 HLA-A*02:01/CMV-sero-
positive donors were A2/CMV-pentamer-positive. The
variable range of A2/CMV-pentamer-positive CD8+ T-cell
frequencies from 0.30% to 6.70% in our test subjects
emphasize the necessity to classify potential donors. Inter-
estingly, we found that the number of CMV-specific mem-
ory T cells present does not correlate with the determined
increase in antigen-specific T-cell frequencies after stimu-
lation with neither the peptide alone nor the complex.
Therefore, we decided to classify the 16 HLA-A*02:01/
CMV-seropositive donors as weak, medium, and strong
responder according to the frequency of generated A2/
CMV-pentamer-positive CD8+ T cells after 1 week stimu-
lation with the well-known CMVpp65495-503 peptide.
Donors classified in these groups belonged there for the
whole stimulation period.
The levels of antiviral CD8+ as well as CD4+ T-cell
responses depend on the peptide. IE-1 and CMVpp65
have been recognized as source of immunodominant anti-
gens that stimulate both cytotoxic and T-helper cells.
HLA class I-restricted peptides derived from these pro-
teins are known to be potent inducers of CTLs [29,31,
32,50], but the obtained responses against CMVpp65 pep-
tides are in general stronger than those described for IE-1-
derived peptides [40,51]. Lacey et al. studied CD8+ T-cell
responses against three human CMVpp65 epitopes in
healthy CMV-seropositive donors [52]. A significant
response was observed to the HLA-A*02-restricted epi-
tope within the CMVpp65 antigen for HLA-A*02:01-posi-
tive donors which do not express the HLA-B*07:02 allele.
By contrast, the strongest responses to CMV in the group
of HLA-A*02:01/HLA-B*07:02-positive donors were
to HLA-B*07-restricted epitopes, indicating that the
HLA-B*07:02-restricted T-cell response was shown to be
dominant over HLA-A*02:01. Here we focused on the
HLA-A*02:01-restricted CMVpp65 peptide to evaluate the
effect of cross-presentation in the expansion of antiviral
T-cells and hypothize, that the observed effects can be
retransmitted to several viral peptides. Cross presentation
of tumor-derived peptides by HSP70 as well as by gp96
was shown before to increase the immune response
[20,47,48,53]. To further study the underlying mechanism
we performed T-cell stimulation using HSP70 complexed
with either A*02:01_CMV-IE-181-89 (n = 5 donors),
A*01:01_CMVpp65363-373 (n = 5 donors), or
B*07:02_CMVpp65417-426 (n = 4 donors) and expanded
these cells over 3 weeks with the described protocol
(Additional file 3). In all experiments we found a strong
increase in the antiviral T-cell response using the respec-
tive HSP70/PC compared to stimulation with the viral
peptides alone. These data support the findings described
in this manuscript.
To assess the activation status of antiviral T cells gen-
erated in vitro we measured expression levels of T-cell
activation markers such as CD25, CD69, and CD137 on
the cell surface [54,55]. Expression levels of all activation
markers used in the present study increased after stimu-
lation. HSP70/CMV-PC induced the highest frequency
of CD25, CD69, and CD137 expression in CD8+ T cells
as well as in A2/CMV-pentamer positive CD8+ T cells.
In this study, we also determined the mRNA expression
levels of HSP70 and HO-1 in activated T cells by quanti-
tative real-time RT-PCR. HSP70 and HO-1, both of
which are inducible cytoprotective stress proteins, have
previously been shown to be up-regulated in response to
similar stimuli [56,57]. But, in particular, the regulation
of HO-1 expression in T cells is not well studied and
contradictory results have been reported. Stimulation
with HSP70/CMV-PC caused a significantly higher
HSP70 and HO-1 mRNA expression levels than either
HSP70 or CMVpp65495-503 peptide alone. Interestingly,
mRNA levels of HO-1 were significantly higher com-
pared to that of HSP70. HO-1 is generally known to be
induced by cellular stress and has major antioxidant and
anti-inflammatory functions [58]. Biburger suggests that
HO-1 may modulate the proliferative capacity of T lym-
phocytes [58]. Another study unexpectedly demonstrated
the activity of HO-1 in human cancer cell during tumor
progression [59]. Here, we demonstrate for the first time
that the HO-1 expression level is up-regulated in specific
CD8+ and CD4+ T cells after stimulation with viral anti-
gens or HSP70, whereas HSP70/CMV-PC can signifi-
cantly increase HO-1 expression.
Compared to unstimulated cells, a slight increase of
secretion of granzyme B was observed after stimulation
with HSP70 alone, which is in concordance with pre-
vious findings [35]. Still stimulation with HSP70/CMV-
PC resulted in the highest granzyme B concentrations
seen.
So far little is known about the “peptide binding motif”
of HSP70 [60]. Therefore, at least three hypotheses have
been proposed to explain the affinity of peptides to
HSP70: 1) Dependent on the hydrophobic residues of the
peptide [19] and on the ATP/ADP-bound state of
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HSP70, the peptide binding may change the conforma-
tion and rigidity of HSP70, potentially altering the choice
of receptors on APCs, which will be used by the respec-
tive HSP70/PCs [19]; 2) Higher affinity may affect pep-
tide processing within the cells by increasing the half-life
as the peptide is protected from proteolytic digestion
[61]; 3) By increasing interaction with the receptor in this
manner, a greater proportion of HSP70 is bound by the
peptide [19]. So far for efficient induction of antigen-spe-
cific cells, HSP70/PC concentrations have been higher
than 50 μg per stimulation [62]. We achieved similar
antigen-specific T-cell responses using only one-tenth of
the typical amount of HSP70/PCs, which has both mate-
rial and cost advantages and might indicate that by using
immunodominant peptides with a high affinity to HSP70,
low concentrations of the antigenic peptide may suffice
to achieve significant increases in antiviral T-cell
responses. However, the analysis of the spin column flow
confirm, that up to 10 μg/ml HSP70/CMV-PC was gen-
erated. Still, the exact concentrations of low-affinity or
weak peptides needed to evoke significant specific T-cell
responses remains to be proven.
Conclusions
In summary, we were able to demonstrate that human
antiviral CTLs can be successfully generated in vitro
using the HSP70/CMV-PC. The intact effector function
of the induced CTLs was demonstrated by functional
assays. Stimulation with HSP70/PCs leads to early pro-
duction of effector cytokines. These findings are consis-
tent with the concept that HSP70/PCs result in efficient
cross-presentation by HLA class I molecules and in sig-
nificantly higher antigen-specific T-cell responses than
non-complexed immunodominant peptides.
Our results clearly indicate that HSP70/CMV-PC can
act as potent mediator for the in vitro generation of the
amounts of antigen-specific T cells needed for adoptive
immunotherapy. Especially in cases of naïve or low CTL
precursor frequencies HSP70-chaperoned peptides
might be useful in clinical applications including the
selective induction of T cells directed against leukemia
targets to increase the graft-versus-leukemia effect, e.g.
by using minor histocompatibility antigen-specific T
cells and the selective expansion of T cells against viral
targets to increase the graft-versus-infection effect. This
approach seems to be a promising method to improve
clinical outcome in children, who have the highest rates
of adenovirus infection, which is associated with high
morbidity and mortality, and where less cells are avail-
able for T-cell induction.
The method for production of recombinant human
HSP70 can be adapted to GMP conditions and can be
used to generate the large amounts of immunogenic
HSP70/peptide or protein complexes needed to generate
antigen-specific T cells for clinical applications.
Additional material
Additional file 1: Flow cytometric analysis of antigen-specific T cells
stimulated with HSP70/CMV-PC and CMVpp65495-503 peptide.
Frequency of A2/CMV-pentamer-positive CD8+ T cells on day 0 and 7, 14
and 21 days after stimulation with recombinant HSP70, respective
CMVpp65495-503 peptide, and HSP70/CMV-PC. Cells cultured in the
presence of the HSP70-peptide-binding buffer served as negative
controls (NC). The donors were divided into three groups (weak: n = 5,
medium: n = 5, strong: n = 6) according to the frequency of generated
A2/CMV-pentamer-positive CD8+ T cells on day 7 (Table 1). Shown are
representative results each with one donor from the group of weak (A),
medium (B), or strong (C) responder.
Additional file 2: Analysis of HSP70/CMV[FITC]-PC, CMVpp65495-503
peptide-FITC, and HSP70-FITC uptake by T-cell subsets using
immunfluorescence microscopy. Representative results of
immunfluorescence microscopy of isolated monocytes from HLA-
A*02:01-positive healthy donor (purity > 98%, Monocyte Isolation Kit II,
Miltenyi Biotech, Bergisch Gladbach, Germany). Immunofluorescence
assay was performed as described elsewhere by Bajor et al. [62]. For the
experiment, 33 mg mg purified HSP70 were conjugated with FITC
(Fluoro tag FITC conjugation Kit, Sigma-Aldrich, Hamburg, Germany) as
well as using FITC-labeled HLA-A*02:01-restricted CMVpp65495-503 peptide
(CMV[FITC], GL Biochem) in a complex with HSP70 (HSP70/CMV[FITC]-PC).
Therefore additional amino acid lysine (K) in the peptide sequences was
required for FITC-labeling of the peptide HSP70/CMV[FITC]-PC and was
prepared as described for the unlabeled complex. 1 × 106 monocytes
were incubated for 4 h with either (A) alone, (B) 10 μg/ml HSP70/CMV
[FITC]-PC, (C) 10 μg/ml FITC-labeled HSP70 (HSP70-FITC), or (D) 10 μg/ml
FITC-labeled CMVpp65495-503 peptide (CMVpp65495-503 peptide-FITC) in
500 μl culture medium (37°C) using 4 well chamber slides (Sigma-Aldrich,
Ontario, Canada). Incubation of CD14+ cells with (B) HSP70/CMV[FITC]-PC
resulted in an increase of uptake in comparison to (C) HSP70-FITC or (D)
CMVpp65495-503 peptide-FITC alone. Analysis was performed on the
Olympus-IX81 microscope (Olympus, PA, USA) with a DAPI and FITC filter
set using a 40X objective. Images were acquired using a CCD camera
(Olympus) and analyzed using Olympus cellIM and cellIR image 3.0
software (Olympus).
Additional file 3: Pentamer staining of antigen-specific CTLs
stimulated with A*02:01_CMV-IE-181-89, A*01:01_CMVpp65363-373, or
B*07:02_CMVpp65417-426 peptides and the respective HSP70/
peptide complexes. Frequency of A2/CMV-IE-181-89-pentamer-positive
CD8+ T cells (A, n = 5), A1/CMVpp65363-373-pentamer-positive CD8
+ T
cells (B, n = 5), and B7/CMVpp65417-426-pentamer-positive CD8
+ T cells (C,
n = 4) from healthy A2/CMV-pentamer-positive donors on day 0 and 7,
14 and 21 days after stimulation with recombinant HSP70, the respective
HLA-restricted CMV peptide or the respective HSP70/PC. Cells cultured in
the presence of the HSP70-peptide-binding buffer served as negative
controls (NC). The donors were divided into three groups (weak,
medium, strong) according to the frequency of generated CMV-
pentamer-positive CD8+ T cells on day 7. The results of the independent
experiments for all donors are expressed as mean ± SD (no division of
the donors in groups). Asterisks shown in the Figure indicate statistically
significances between levels in CMV peptide- and respective HSP70/PC-
stimulated cells (*p < 0.05, ** p < 0.01).
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